🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Our CEO Raymond Stevens, Ph.D., joined CNBC's Fast Money to discuss Structure's role in developing oral #smallmolecule treatments for #obesity. In an area with significant unmet medical need, we're leveraging a small molecule approach to address the scalability limitations of

We're excited to announce the selection of our lead oral small molecule amylin receptor agonist, ACCG-2671. #Amylin is a promising therapeutic target for #obesity and related diseases due to its effects on reducing food intake and slowing gastric emptying. ACCG-2671 was designed

As we reflect on another remarkable year, we’re proud to celebrate the milestones that have shaped our journey at Structure. 2024 has been a testament to our team's dedication and our collective mission of advancing our clinical-stage pipeline in #obesity and in multiple disease

What an exciting #JPM25! Our CEO Raymond Stevens shared our upcoming milestones and mission of greater accessibility for #obesity treatments with both CNBC's Angelica Peebles and Bloomberg's Katie Greifeld. #SmallMolecule approaches, like the ones we are taking here at Structure,

We have launched our new website! This transformation is more than a new look—it's a reaffirmation of our mission, our passion, and our relentless drive to make medicines more accessible to all. Patients are waiting for treatment options that are available, cost effective, and

In honor of International Day of Women and Girls in Science, we are pleased to introduce our Women’s Leadership Network, Structure’s global internal organization dedicated to women’s empowerment, leadership and excellence. Hear from our founding members below on why we believe

What better way to kick off the year than by bringing the full U.S. team together to celebrate our wins and set the stage for another year of growth. Congratulations to the recipients of our Foundation Awards. We believe strong foundations make bold visions possible. We

Today, we reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update. Read the top highlights below and view the full announcement here: ir.structuretx.com/news-releases/… ➡️ Aleniglipron (GSBR-1290) ACCESS and ACCESS II studies

We're proud to sponsor Beyond Type 1's “Let’s Talk Clinical Trials” campaign, aimed at educating the #diabetes community on clinical trials through a variety of educational resources. Check out the article below which debunks common myths about clinical trials.

Today is #WorldObesityDay, a time to raise awareness, and advocate for better care and solutions for those living with #obesity, which affects hundreds of millions worldwide. We're advancing oral #smallmolecule medicines designed for the treatment of obesity with a goal of

During yesterday's #WorldObesityDay, we had the privilege of hosting OAC board member Elizabeth Paul at our office in South San Francisco. Liz advocates for body positivity, standing up against bias, and promoting care and respect from health professionals and more.

In honor of #InternationalWomensDay, our team in Shanghai welcomed a psychology expert to explore the importance of mindfulness, stress management, and self-care, followed by a meditation and yoga session. In addition, our team in South San Francisco participated in a series of

In celebration of #WomensHistoryMonth, meet Tracy Fajardo, Structure's senior manager of patient recruitment and retention and a key player of the Healthcare Businesswomen’s Association (HBA). Tracy is not only dedicated to improving patient experiences in clinical trials but

2025 is the year of the oral #smallmolecule which we believe is the best solution for long term, impactful weight loss for patients living with #obesity. Our CEO Raymond Stevens joined Melissa Lee, host of CNBC's Fast Money, and others at the roundtable to discuss the importance

Today, we reported financial results for the first quarter ended March 31, 2025, and provided a business update. See the highlights below and read full announcement here: ir.structuretx.com/news-releases/… ➡️ Topline data from oral small molecule aleniglipron (GSBR-1290) Phase 2b ACCESS and

Today, on #ClinicalTrialsDay, we recognize the individuals who participate in clinical research and the investigators, coordinators and teams who help us bring new medicines to life. At Structure, we’re focused on transforming drug development through oral #smallmolecule

We’re participating in the Jefferies and Goldman Sachs Global Healthcare Investor Conferences in June. Read the details below and here to access the live and archived presentation webcasts: ir.structuretx.com/news-releases/…

We’re at #ADASciSessions! Among the data we're presenting is new preclinical data related to ACCG-2671, our #smallmolecule amylin receptor agonist for #obesity, expected to enter clinical development this year. Visit us at our booth to learn more, and read the details here:

We’re back from an inspiring few days at #ADASciSessions, where the energy around innovation in the obesity field was truly remarkable. It was a milestone moment for Structure as we debuted our first-ever medical booth and shared exciting preclinical data from our oral